Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Sarcoma
90%
Soft Tissue Sarcoma
66%
Chemotherapy
65%
Tumor
61%
Gastrointestinal Stromal Tumor
53%
Phase I Study
48%
Osteosarcoma
39%
Overall Survival
35%
Doxorubicin
30%
Imatinib
29%
Adriamycin
27%
Ewing Sarcoma
26%
Phase I Trial
23%
Phase II Trial
23%
Partial Response
22%
Clinical Trials
22%
Granulocyte Colony-stimulating Factor (G-CSF)
21%
95% Confidence Interval
20%
Progression-free Survival
20%
Radiation Therapy
20%
Targeted Therapy
19%
Solid Tumors
19%
Synovial Sarcoma
19%
Dedifferentiated Liposarcoma (DDLPS)
18%
Older Adults
17%
Systemic Therapy
17%
Stable Disease
17%
Radiotherapy
17%
Cancer Patients
16%
Surgical Resection
15%
Response Rate
14%
Prognostic Factors
14%
Melanoma
14%
Angiosarcoma
14%
In Cancer
14%
Resection
14%
Local Recurrence
14%
Clinical Outcomes
14%
Liposarcoma
13%
Ifosfamide
13%
Metastatic Disease
13%
Local Control
13%
Leiomyosarcoma
13%
Thrombocytopenia
13%
Metastatic Melanoma
13%
High Risk
12%
Imatinib Mesylate
12%
Advanced Gastrointestinal Stromal Tumor
12%
Gemcitabine
12%
Metastasis
12%
Pazopanib
12%
Anthracyclines
11%
Complete Response
11%
Cisplatin
11%
Dacarbazine
11%
Desmoid Tumor
11%
Combined Modality Therapy
11%
Tumor Size
11%
Patient Outcomes
10%
Hazard Ratio
10%
Undifferentiated Pleomorphic Sarcoma
10%
Adjuvant Therapy
10%
Disease-free Survival
10%
Bone Sarcoma
10%
Median Progression-free Survival
10%
MD Anderson Cancer Center
10%
Well Tolerated
10%
Median Overall Survival
10%
Recurrent Disease
10%
Trabectedin
10%
Myelosuppression
9%
Malignancy
9%
Cyclophosphamide
9%
Patients with Cancer
9%
Primary Tumor
9%
Disease-specific Survival
9%
Oncology
9%
Myxoid Liposarcoma
9%
Soft Tissue
9%
Progressive Disease
9%
Distant Metastasis
9%
Continuous Infusion
9%
Disease Progression
9%
Bone Marrow
9%
Response Evaluation Criteria in Solid Tumors (RECIST)
9%
Head-and-neck
8%
Combination Chemotherapy
8%
Growth Factors
8%
Clinical Practice Guidelines
8%
Liver
8%
Preoperative Chemotherapy
8%
Localized Disease
8%
Chondrosarcoma
8%
Spine
8%
Advanced Soft Tissue Sarcoma
8%
Duration of Response
8%
Survivors
8%
Denosumab
8%
Platelet-derived Growth Factor Receptor (PDGFR)
8%
Antitumor Activity
8%
Medicine and Dentistry
Connective Tissue Cancer
100%
Chemotherapy
74%
Soft Tissue Sarcoma
66%
Diseases
64%
Neoplasm
63%
Malignant Neoplasm
49%
Gastrointestinal Stromal Tumor
46%
Overall Survival
43%
Tumor
43%
Radiation Therapy
38%
Recurrent Disease
36%
Osteosarcoma
33%
Doxorubicin
31%
Adolescence
30%
Imatinib
28%
Progression Free Survival
23%
Clinical Trial
23%
Ewing Sarcoma
22%
Metastatic Carcinoma
22%
Systemic Therapy
20%
Cancer
19%
Oncology
18%
Synovial Sarcoma
17%
Targeted Therapy
16%
Angiosarcoma
16%
Prognostic Factor
15%
Leiomyosarcoma
15%
Solid Malignant Neoplasm
15%
Cisplatin
14%
Melanoma
13%
Liposarcoma
13%
Cancer in Young Adults
12%
Desmoid Tumor
11%
Anthracycline
10%
Immunotherapy
10%
Ifosfamide
10%
Survival Rate
10%
Genetics
10%
Chondrosarcoma
10%
Adverse Event
10%
Arm
10%
Thrombocytopenia
9%
Primary Tumor
9%
Disease Free Survival
9%
Adjuvant Therapy
9%
Hazard Ratio
9%
Dedifferentiated Liposarcoma
9%
Rhabdomyosarcoma
8%
Median Follow Up
8%
Neck
8%
Dacarbazine
8%
Pazopanib
8%
Disease Specific Survival
8%
Retrospective Study
7%
Lung
7%
Thrombopoietin
7%
Cardiotoxicity
7%
Preoperative Chemotherapy
7%
Computer Assisted Tomography
7%
Gemcitabine
7%
Chordoma
7%
Histology
7%
Platelet
7%
Quality of Life
7%
Denosumab
7%
Recurrence Free Survival
6%
Well Differentiated Liposarcoma
6%
Distant Metastasis
6%
Adjuvant Chemotherapy
6%
Tyrosine-Kinase Inhibitor
6%
Neoadjuvant Chemotherapy
6%
Magnetic Resonance Imaging
6%
Infusion
6%
Localized Disease
6%
Cyclophosphamide
6%
Long-Term Outcome
6%
Surgery
6%
Lung Metastasis
6%
Placebo
6%
Bone Cancer
6%
Biological Marker
6%
Treatment Option
6%
Metastatic Melanoma
6%
Surgical Margin
5%
Cytokine
5%
Long Term Survival
5%
Pediatrics
5%
Progressive Disease
5%
Exon
5%
Drug Megadose
5%
Disease Exacerbation
5%
Growth Factor
5%
Oral
5%
T Cell
5%
Desmoplastic Small Round Cell Tumor
5%
Giant Cell Tumor
5%
Phase II Trials
5%
COVID-19
5%
Surgeon
5%
Malignant Fibrous Histiocytoma
5%